A Novel Combretastatin A-4 Derivative, AC-7700, Shows Marked Antitumor Activity against Advanced Solid Tumors and Orthotopically Transplanted Tumors

• NIHEI Yukio

  Pharmaceutical Research Laboratories, Ajinomoto Co., Inc

• SUGA Yasuyo

  Pharmaceutical Research Laboratories, Ajinomoto Co., Inc

• MORINAGA Yoshihiro

  Pharmaceutical Research Laboratories, Ajinomoto Co., Inc

• OHISHI Kazuo

  Pharmaceutical Research Laboratories, Ajinomoto Co., Inc

• OKANO Akira

  Pharmaceutical Research Laboratories, Ajinomoto Co., Inc

• OHSUMI Koji

  Pharmaceutical Research Laboratories, Ajinomoto Co., Inc

• HATANAKA Toshihiro

  Pharmaceutical Research Laboratories, Ajinomoto Co., Inc

• NAKAGAWA Ryusuke

  Pharmaceutical Research Laboratories, Ajinomoto Co., Inc

• TSUJI Takashi

  Pharmaceutical Research Laboratories, Ajinomoto Co., Inc

• AKIYAMA Yukio

  Pharmaceutical Research Laboratories, Ajinomoto Co., Inc

• SAITO Sachiko

  Department of Vascular Biology, Institute of Development, Aging and Cancer, Tohoku University

• HORI Katsuyoshi

  Department of Vascular Biology, Institute of Development, Aging and Cancer, Tohoku University

• SATO Yasufumi

  Department of Vascular Biology, Institute of Development, Aging and Cancer, Tohoku University

• TSURUO Takashi

  Laboratory of Biomedical Research, Institute of Molecular and Cellular Biosciences, University of Tokyo

Journal

• Jpn J Cancer Res

  Jpn J Cancer Res 90 (9), 1016-1025, 1999-09-30

Keywords

• Combretastatin
• Tubulin-binding agent
• Advanced solid tumor
• Orthoropic transplantation
• Host immune status

Details

• CRID: 1573105974484418816
• NII Article ID: 10008092683
• NII Book ID: AA00690844
• ISSN: 09105050
• Web Site: https://search.jamas.or.jp/link/ui/2000079361
• Text Lang: en
• Data Source:
  • CiNii Articles